Miach Orthopaedics closed a $40 million financing round. The funds will enable ongoing operations and expand the U.S. commercial rollout of the company’s Bridge-Enhanced ACL Restoration (BEAR) Implant for the treatment of anterior cruciate ligament (ACL) tears.
The financing includes contributions from Smith+Nephew and the NFL Players Association.
The BEAR Implant serves as a bridge to restore the patient’s own ACL, and is reportedly the first medical technology that has been clinically proven to enable the healing of a torn ACL. Unlike reconstruction, which is the current standard of care, the BEAR Implant does not require a second surgical wound site to remove a healthy tendon from another part of the leg or the use of a donor tendon. The device is resorbed by the body as the ACL heals.
“Since launching our BEAR Implant in fall 2021, we’ve received tremendous interest from both surgeons and patients alike, who understand the benefits of healing a torn ACL rather than replacing it,” said Patrick McBrayer, President and CEO, Miach Orthopaedics. “More than 500 patients have been treated with the BEAR Implant commercially. This additional investment will allow us to expand our presence nationwide and bring the benefits of ACL restoration to more patients with ACL tears.”
Miach Orthopaedics closed a $40 million financing round. The funds will enable ongoing operations and expand the U.S. commercial rollout of the company's Bridge-Enhanced ACL Restoration (BEAR) Implant for the treatment of anterior cruciate ligament (ACL) tears.
The financing includes contributions from Smith+Nephew and the NFL Players...
Miach Orthopaedics closed a $40 million financing round. The funds will enable ongoing operations and expand the U.S. commercial rollout of the company’s Bridge-Enhanced ACL Restoration (BEAR) Implant for the treatment of anterior cruciate ligament (ACL) tears.
The financing includes contributions from Smith+Nephew and the NFL Players Association.
The BEAR Implant serves as a bridge to restore the patient’s own ACL, and is reportedly the first medical technology that has been clinically proven to enable the healing of a torn ACL. Unlike reconstruction, which is the current standard of care, the BEAR Implant does not require a second surgical wound site to remove a healthy tendon from another part of the leg or the use of a donor tendon. The device is resorbed by the body as the ACL heals.
“Since launching our BEAR Implant in fall 2021, we’ve received tremendous interest from both surgeons and patients alike, who understand the benefits of healing a torn ACL rather than replacing it,” said Patrick McBrayer, President and CEO, Miach Orthopaedics. “More than 500 patients have been treated with the BEAR Implant commercially. This additional investment will allow us to expand our presence nationwide and bring the benefits of ACL restoration to more patients with ACL tears.”
Copy to clipboard 
